Vaxcell-Bio Therapeutics

At a glance

Vaxcell-Bio Therapeutics filed 24 disclosures in the last 12 months, including 5 insider and 1 5% holder. The most recent key filing was on Mar 27.

Revenue for 2025 was ₩7.1B, up 271.6% on 2024. It made an operating loss of ₩15.5B. Debt was 9% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩3.2B and operating loss of ₩9.6B.

The 2025 annual report lists 91 employees with an average tenure of 2.6 years and average pay of ₩49.3M, #1479 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩112M each on average. It paid no cash dividend for 2025. 이제중 and related parties held 12.48% at year end.

From the 2025 annual report

Staff: 91 (44 men, 47 women), of whom 13 on fixed-term contracts. Total pay for the year: ₩5B. Directors and auditors: 4, paid ₩448M in total.

No cash dividend was paid for 2025.

Largest shareholder

이제중 holds 9.22%; with 27 related parties the group holds 12.48% of common shares at year end (from 12.84% at the start of the year).

Auditor: 동현회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary